Analyzing...
Loading company...
Kilpest India Ltd. engages in the manufacture of pesticides and fertilizers. The company is headquartered in Bhopal, Madhya Pradesh. The company is engaged in the manufacture of pesticide products, micro fertilizers, biofertilizers, and biopesticides. Its agricultural businesses include crop protection, public health products and bio-products. The company provides chemical products, which includes insecticides, such as Bheem, Proud, Kildon, Shock, Fighter, Sumo, Sumo Plus, Kilgrip, Razor, and Kilthion; anti-bacterial product, which include Kiltomycin; fungicides, such as Blue-vit, Micfun, Ajomil, Prahar 80 WP, and Blast; weedicides, such as Kilweed 38E, Stump, Chapet, Glyphokil, and Eraser and public health products, such as Kilvos76E, Bazooka, Kilothus, Kropmal WP, and Kilthion GR. The company offers biological products, such as LARVECT 50, Mahakaal and Neemkil; bio fungicides, which include Suraksha; bio fertilizers, such as Fytozyme, Sampada, Neemayu, and Vardhak-90; bio nematicides; public health products, such as Roach Kill, Ann Rakshak, and Repel-Mos, and health and hygiene products.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Hospitals & Diagnostics.”
₹142 Cr revenue.
COGS 25.3%, employees 16.9%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 18.1%▲ | 9.0% |
| ROCE | 22.6%▲ | 10.4% |
| Net Margin | 35.0%▲ | 8.5% |
| EBITDA Margin | 49.2%▲ | 20.6% |
| Debt To Equity | 0.01x▼ | 0.16x |
| Rev Growth 3yr | 34.4%▲ | 14.4% |
| EPS Growth 3yr | 31.3%▲ | 9.9% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹142 Cr +47.1% | ₹96 Cr +30.1% | ₹74 Cr +19.9% | ₹62 Cr -23.3% | ₹81 Cr -64.4% | ₹227 Cr +685.3% | ₹29 Cr +24.0% | ₹23 Cr |
| Other Income | ₹26 Cr +69.4% | ₹15 Cr +20.4% | ₹13 Cr +73.4% | ₹7 Cr +4.7% | ₹7 Cr +138.7% | ₹3 Cr +80.8% | ₹2 Cr +115.7% | ₹0.74 Cr |
| Total Income | ₹167 Cr +50.1% | ₹112 Cr +28.7% | ₹87 Cr +25.5% | ₹69 Cr -21.1% | ₹88 Cr -61.9% | ₹230 Cr +653.5% | ₹30 Cr +26.9% | ₹24 Cr |
| COGS | ₹36 Cr +39.8% | ₹26 Cr +17.4% | ₹22 Cr +21.9% | ₹18 Cr -43.3% | ₹32 Cr -38.7% | ₹52 Cr +288.9% | ₹13 Cr +22.4% | ₹11 Cr |
| ₹91 Cr +90.3% | ₹48 Cr +12.4% | ₹42 Cr +25.4% | ₹34 Cr -23.9% | ₹44 Cr -42.9% | ₹78 Cr +279.9% | ₹20 Cr +19.7% | ₹17 Cr | |
| Profit Before Tax | ₹77 Cr +20.3% | ₹64 Cr +44.4% | ₹44 Cr +25.6% | ₹35 Cr -18.3% | ₹43 Cr -71.6% | ₹152 Cr | ₹10 Cr +44.6% | ₹7 Cr |
| ₹17 Cr +4.5% | ₹16 Cr +33.3% | ₹12 Cr +30.5% | ₹9 Cr -15.0% | ₹11 Cr -71.1% | ₹38 Cr | ₹2 Cr +38.3% | ₹2 Cr | |
| Net Profit | ₹60 Cr +25.7% | ₹48 Cr +48.6% | ₹32 Cr +23.8% | ₹26 Cr -19.4% | ₹32 Cr -71.7% | ₹114 Cr | ₹8 Cr +46.7% | ₹5 Cr |
| Profit (Owners) | ₹59 Cr +22.9% | ₹48 Cr +45.6% | ₹33 Cr +44.4% | ₹23 Cr -19.6% | ₹28 Cr -71.7% | ₹100 Cr | ₹7 Cr +35.5% | ₹5 Cr |
| Minority Interest | ₹1 Cr | ₹0.04 Cr ↑ Recovery | (₹0.63 Cr) ↓ Decline | ₹3 Cr -18.2% | ₹4 Cr -71.6% | ₹14 Cr | ₹0.89 Cr +298.5% | ₹0.22 Cr |
| EPS | ₹68.26 | ₹55.52 | ₹38.14 | ₹30.19 | ₹37.56 | ₹132.91 | ₹9.06 | ₹7.83 |
| Diluted Shares | ₹0.86 Cr | ₹0.86 Cr | ₹0.86 Cr | ₹0.75 Cr | ₹0.75 Cr | ₹0.75 Cr | ₹0.75 Cr | ₹0.64 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Schedule of Analyst/ Investor Meeting
Special Window for Re-lodgement of Transfer Requests of Physical shares
Transcript of Analysts/Investors Call pertaining to the Financial Results for the third quarter and nine months ended December 31, 2025
Audio Recording of Analysts/Investors Call pertaining to the Unaudited Financial Results for the third quarter and nine months ended December 31, 2025
Letter for Updation
Intimation of Re-Scheduling of the Earning Concall under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
Submission of Advertisement Clipping of the extract of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2025
Investor''s Presentation
Submission of Unaudited Financial Results of the Company for the quarter and Nine Months ended December 31, 2025
Submission of Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025
3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve the Unaudited Standalone and .... 3B Black...
Certificate under Reg.74(5) of SEBI (DP)Regulations, 2018
Special Window for Re-lodgement of Transfer Requests of Physical Shares
Closure of Trading Window
Disclosure Under Regulation 29(2) of SEBI (SAST) Regulations, 2011
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.